[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022010980A - Composiciones y metodos para el suministro de arn dirigido. - Google Patents

Composiciones y metodos para el suministro de arn dirigido.

Info

Publication number
MX2022010980A
MX2022010980A MX2022010980A MX2022010980A MX2022010980A MX 2022010980 A MX2022010980 A MX 2022010980A MX 2022010980 A MX2022010980 A MX 2022010980A MX 2022010980 A MX2022010980 A MX 2022010980A MX 2022010980 A MX2022010980 A MX 2022010980A
Authority
MX
Mexico
Prior art keywords
methods
compositions
targeted rna
rna delivery
pcsk9
Prior art date
Application number
MX2022010980A
Other languages
English (en)
Inventor
Padma Malyala
Kallanthottathil G Rajeev
Souvik Biswas
Lisa N Kasiewicz
Alexandra Chadwick
Caroline Reiss
Original Assignee
Verve Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verve Therapeutics Inc filed Critical Verve Therapeutics Inc
Publication of MX2022010980A publication Critical patent/MX2022010980A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Optics & Photonics (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan en la presente composiciones, métodos para fabricar las mismas y métodos para el suministro dirigido de agentes terapéuticos para la modificación de la expresión y la función de los genes objetivo, por ejemplo, proteínas involucradas en el metabolismo de lípidos y el colesterol, tales como PCSK9. Además, se proporcionan en la presente composiciones y métodos para el tratamiento de condiciones relacionadas con la enfermedad coronaria.
MX2022010980A 2020-03-04 2021-03-04 Composiciones y metodos para el suministro de arn dirigido. MX2022010980A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984866P 2020-03-04 2020-03-04
US202063078982P 2020-09-16 2020-09-16
PCT/US2021/020955 WO2021178725A1 (en) 2020-03-04 2021-03-04 Compositions and methods for targeted rna delivery

Publications (1)

Publication Number Publication Date
MX2022010980A true MX2022010980A (es) 2022-12-02

Family

ID=77612786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010980A MX2022010980A (es) 2020-03-04 2021-03-04 Composiciones y metodos para el suministro de arn dirigido.

Country Status (12)

Country Link
US (4) US11207416B2 (es)
EP (1) EP4114360A4 (es)
JP (1) JP2023516759A (es)
KR (1) KR20230011913A (es)
CN (1) CN115484932A (es)
AU (1) AU2021230367A1 (es)
BR (1) BR112022017688A2 (es)
CA (1) CA3174708A1 (es)
GB (6) GB2613225B (es)
IL (1) IL296133A (es)
MX (1) MX2022010980A (es)
WO (1) WO2021178725A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207712A2 (en) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Base editing of pcsk9 and methods of using same for treatment of disease
MX2023006056A (es) 2020-11-25 2023-06-06 Akagera Medicines Inc Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
EP4380576A2 (en) * 2021-08-03 2024-06-12 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
WO2023212622A1 (en) * 2022-04-26 2023-11-02 University Of Virginia Patent Foundation SUGAR-CONJUGATED LIPID NANOPARTICLES FOR TARGETED DELIVERY OF siRNA TO HEPATOCYTES
WO2023220454A1 (en) * 2022-05-13 2023-11-16 Twister Biotech, Inc. Conjugated composition and method for delivering a therapeutic nucleic acid sequence to a living cell
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024074666A1 (en) * 2022-10-06 2024-04-11 Mireca Medicines Gmbh Conjugates for neuroretinal drug delivery
WO2024197310A1 (en) * 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197309A1 (en) * 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197307A1 (en) * 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689042A1 (en) * 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
EP2231195B1 (en) 2007-12-04 2017-03-29 Arbutus Biopharma Corporation Targeting lipids
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
CA3036963A1 (en) * 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
US8158601B2 (en) * 2009-06-10 2012-04-17 Alnylam Pharmaceuticals, Inc. Lipid formulation
JP5823405B2 (ja) * 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
MX2015005792A (es) * 2012-11-15 2015-12-17 Roche Innovation Ct Copenhagen As Compuestos de conjugado antisentido anti apob.
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US20140287024A1 (en) * 2013-03-08 2014-09-25 Shu Wang Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis
KR102226110B1 (ko) 2013-06-27 2021-03-10 로슈 이노베이션 센터 코펜하겐 에이/에스 Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체
EP3872066A1 (en) * 2013-12-19 2021-09-01 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
DK3129067T5 (da) * 2014-03-19 2024-10-14 Genzyme Corp Sitespecifik glycomodificering af målsøgningsdele
KR20170135932A (ko) * 2015-04-13 2017-12-08 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
AU2019213004B2 (en) * 2018-01-29 2024-03-07 F. Hoffmann-La Roche Ag Process for the preparation of GalNAc oligonucleotide conjugates
CN113286882A (zh) * 2018-11-09 2021-08-20 阿布特斯生物制药公司 脂质纳米颗粒制剂
EP4359529A1 (en) * 2021-06-24 2024-05-01 Eli Lilly and Company Novel therapeutic delivery moieties and uses thereof

Also Published As

Publication number Publication date
US11207416B2 (en) 2021-12-28
GB202406904D0 (en) 2024-06-26
GB2613225A (en) 2023-05-31
GB2621760A (en) 2024-02-21
GB202407662D0 (en) 2024-07-17
GB2626889A (en) 2024-08-07
US20210299261A1 (en) 2021-09-30
US20220152210A1 (en) 2022-05-19
GB2629329A (en) 2024-10-23
WO2021178725A1 (en) 2021-09-10
GB202407746D0 (en) 2024-07-17
IL296133A (en) 2022-11-01
US20240100169A1 (en) 2024-03-28
GB2627637A (en) 2024-08-28
CN115484932A (zh) 2022-12-16
GB2627644A (en) 2024-08-28
EP4114360A1 (en) 2023-01-11
US20240131166A1 (en) 2024-04-25
KR20230011913A (ko) 2023-01-25
GB2621760B (en) 2024-09-11
US11801306B2 (en) 2023-10-31
GB202213818D0 (en) 2022-11-09
AU2021230367A1 (en) 2022-09-29
GB202411424D0 (en) 2024-09-18
GB2613225B (en) 2024-01-03
CA3174708A1 (en) 2021-09-10
EP4114360A4 (en) 2024-06-26
BR112022017688A2 (pt) 2022-11-16
JP2023516759A (ja) 2023-04-20
GB2626889B (en) 2024-10-23

Similar Documents

Publication Publication Date Title
MX2022010980A (es) Composiciones y metodos para el suministro de arn dirigido.
MX2022003402A (es) Grupos principales de compuestos lipídicos y composiciones para la administración intracelular de agentes terapéuticos.
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
ES2537568T3 (es) Nuevos fármacos para inhibición de la expresión genética
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
BR112022020795A2 (pt) Métodos para edição alvejada de um ácido ribonucleico alvo e para prevenir ou tratar síndrome de hurler, ácido ribonucleico de recrutamento da adenosina desaminase engenheirado, construção, e, composição, lipossoma, exossoma, nanopartícula de lipídeo, célula, biblioteca ou kit
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
SG161267A1 (en) Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2022036126A3 (en) RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
MXPA05011221A (es) Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.
WO2023015223A3 (en) Compositions and methods for targeted rna delivery
MX2023002883A (es) Conjugados lipidicos para el transporte de agentes terapeuticos.
WO2022040641A3 (en) Functional ionizable phospholipids
MX2023005198A (es) Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
MX2022006846A (es) Conjugados y metodos para tratar la fibrosis hepatica.
Castro et al. Mini-review: nucleus-targeted ribonucleases as antitumor drugs
MX2024000085A (es) Terapeutica con arn novedosos y usos de estos.
WO2023081500A3 (en) RNAi OLIGONUCLEOTIDE CONJUGATES
Iwata et al. Synthesis and properties of vitamin E analog-conjugated neomycin for delivery of RNAi drugs to liver cells
EA202190800A1 (ru) РНКи АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ 17БЕТА-HSD ТИПА 13 (HSD17B13), ИХ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ
AR126179A1 (es) AGENTES DE RNAi PARA INHIBIR LA EXPRESIÓN DE XANTINA DESHIDROGENASA (XDH), COMPOSICIONES FARMACÉUTICAS DE ESTOS Y MÉTODOS DE USO